Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 4/20 | 0.44 |
| ▸ | MAOB | P27338 | 4/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 3/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.39 |
| ▸ | DRD1 | P21728 | 4/20 | 0.38 |
| ▸ | DRD5 | P21918 | 4/20 | 0.38 |
| ▸ | DRD2 | P14416 | 3/20 | 0.38 |
| ▸ | DRD4 | P21917 | 3/20 | 0.38 |
| ▸ | DRD3 | P35462 | 3/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8054291 | 0.85 | MAOA (0.44) | PNMTMAOAMAOBSLC6A4PARP1 | |
| SCHEMBL788195 | 0.79 | MAOA (0.42) | PNMTMAOAMAOBSLC6A4PARP1 | |
| SCHEMBL16869981 | 0.79 | PARP1 (0.43) | MAOAMAOBSLC6A4PARP1PARP2 | |
| SCHEMBL2925102 | 0.77 | MAOA (0.40) | MAOAMAOBSLC6A4PARP1PARP2 | |
| SCHEMBL19398846 | 0.77 | HDAC6 (0.43) | MAOAMAOBSLC6A4PARP1PARP2 | |
| SCHEMBL16624079 | 0.77 | PNMT (0.42) | PNMTPRMT5WDR77 | |
| SCHEMBL19406817 | 0.77 | KCNH2 (0.45) | MAOAMAOBSLC6A4PARP1PARP2 | |
| SCHEMBL19782459 | 0.77 | MAOA (0.40) | MAOAMAOBSLC6A4PARP1PARP2 | |
| SCHEMBL16869982 | 0.77 | MAOA (0.50) | MAOAMAOBSLC6A4PARP1PARP2 | |
| SCHEMBL25797192 | 0.77 | PNMT (0.42) | PNMTPARP1PARP2DRD2PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4400505-A1 | PEPTIDE-UREA DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND APPLICATION THEREOF | Bivision Pharmaceuticals, Inc (CN) | 2024-07-17 | — | — | EP | disclosed |
| WO-2023116812-A1 | SULFONYLUREA COMPOUND | 瑞石生物医药有限公司 | 2023-06-29 | — | — | WO | disclosed |
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2023-06-15 | — | — | US | disclosed |
| WO-2022161420-A1 | CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊石医药科技有限公司 | 2022-08-04 | — | — | WO | disclosed |
| EP-3647311-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | Beijing Tide Pharmaceutical Co., Ltd. (CN) | 2020-05-06 | — | — | EP | disclosed |
| US-10246470-B2 | Heterocyclic compounds | CADILA HEALTHCARE LIMITED (IN) | 2019-04-02 | — | — | US | disclosed |
| US-10011609-B2 | Heterocyclic compounds | CADILA HEALTHCARE LIMITED (IN) | 2018-07-03 | — | — | US | disclosed |
| US-10011609-B2 | Heterocyclic compounds | CADILA HEALTHCARE LIMITED (IN) | 2018-07-03 | — | — | US | disclosed |
| US-20160257701-A1 | NOVEL HETEROCYCLIC COMPOUNDS | CADILA HEALTHCARE LIMITED (IN) | 2016-09-08 | — | — | US | disclosed |
| US-20110021494-A1 | NOVEL TETRAHYDRO-FUSED PYRIDINES AS HISTONE DEACETYLASE INHIBITORS | 4SC AG (DE) | 2011-01-27 | — | — | US | disclosed |
| EP-2054421-B1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO KGAA (DE) | 2010-11-17 | — | — | EP | disclosed |
| US-20100261908-A1 | PROCESSES FOR THE PREPARATION OF PRASUGREL , AND ITS SALTS AND POLYMORPHS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-10-14 | — | — | US | disclosed |
| EP-2090576-A1 | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators | Merz Pharma GmbH & Co.KGaA (DE) | 2009-08-19 | — | — | EP | disclosed |
| WO-2009095253-A1 | 6-HALO-PYRAZOLO[1, 5-A]PYRIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR (MGLUR) MODULATORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-08-06 | — | — | WO | disclosed |
| EP-2054421-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | Merz Pharma GmbH & Co. KGaA (DE) | 2009-05-06 | — | — | EP | disclosed |
| WO-2009037001-A2 | NOVEL TETRAHYDROFUSEDPYRIDINES AS HISTONE DEACETYLASE INHIBITORS | 4SC AG (DE) | 2009-03-26 | — | — | WO | disclosed |
| US-20080039476-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-14 | — | — | US | disclosed |
| WO-2008015270-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | WO | disclosed |
| US-20070185077-A1 | Methods of treating, preventing and inhibiting cancer metastasis and tumor formation | WASHINGTON UNIVERSITY | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185077-A1 | Methods of treating, preventing and inhibiting cancer metastasis and tumor formation | ITGB3, ITGB1, ITGA2B | PNMT 3600/4885MAOA 4679/4885MAOB 2302/4885 |
| US-20110021494-A1 | NOVEL TETRAHYDRO-FUSED PYRIDINES AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC3 | PNMT 3398/4885MAOA 1513/4885MAOB 1075/4885 |
| US-10011609-B2 | Heterocyclic compounds | GPR55, GPR68, GPR65 | PNMT 2572/4885MAOA 1986/4885MAOB 2013/4885 |
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, STING1 | PNMT 2059/4885MAOA 2128/4885MAOB 2576/4885 |
| US-10246470-B2 | Heterocyclic compounds | HAAO, HK1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PNMT 1658/4885MAOA 179/4885MAOB 137/4885 |
| US-20100261908-A1 | PROCESSES FOR THE PREPARATION OF PRASUGREL , AND ITS SALTS AND POLYMORPHS | PFKP, CYP2C19, CYP2C9 | PNMT 3754/4885MAOA 2110/4885MAOB 1883/4885 |
| US-20080039476-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | GRM5, GRM3, GRM1 | PNMT 1648/4885MAOA 2093/4885MAOB 912/4885 |
| US-20160257701-A1 | NOVEL HETEROCYCLIC COMPOUNDS | GPR55, GPR68, GPR65 | PNMT 3159/4885MAOA 2073/4885MAOB 2018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.